分流泵灌注试验:对患者结局的影响及卫生经济学评价
该研究纳入2013年1月至2015年12月接受灌注试验的脑积水或假性脑瘤综合征(PTCS)分流患者,随访6和12个月,评估灌注试验鉴别分流功能正常与可能故障的准确性及经济后果。结果显示超过290例不必要的分流翻修被避免,258例(>85%)非手术管理者保持良好,剑桥每年节省945415英镑。
要点
- 在脑积水分流患者中,约55%(155/280)的灌注试验显示无分流故障,125例可能存在故障。
- PTCS患者中47例存在可能问题,38例无分流故障指征。
- 3年内避免超过290例不必要的翻修,258例(>85%)非手术管理者保持良好且无需手术。
核心结论
- 灌注试验有助于在体内确认分流故障,避免不必要的分流翻修对患者有显著健康获益,并为国家医疗服务体系及全球其他医疗系统带来显著经济收益。
研究设计与样本
- 纳入2013年1月至2015年12月接受灌注试验的脑积水或PTCS分流患者,随访6和12个月评估改善、持续症状或需紧急翻修情况,并计算翻修与灌注试验及标准翻修加颅内压监测方案与灌注试验的总费用节省。
主要发现
- 脑积水患者中,超过一半的试验(约55%,155/280)显示无分流故障,125例可能存在故障(年龄4个月至90岁)。
- PTCS患者年龄10至77岁,47例存在可能问题,38例无分流故障指征。
- 3年内避免超过290例不必要的翻修;258例(>85%)非手术管理者保持良好,未恶化且无需手术。
- 灌注试验未发生相关感染;剑桥每年因避免翻修节省945415英镑。
临床怎么用
- 作者认为灌注试验在体内确认分流故障具有重要价值,避免不必要的分流翻修对患者有显著健康获益并带来显著经济收益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The diagnosis of shunt malfunction is often not straightforward. We have explored, in symptomatic shunted patients with hydrocephalus or pseudotumour cerebri syndrome (PTCS), the accuracy of CSF infusion tests in differentiating a functioning shunt from one with possible problems, and the health economic consequences. METHODS: Participants: hydrocephalus/PTCS patients with infusion tests performed from January 2013 until December 2015. We followed patients up after 6 and 12 months from the test to determine whether they had improved, had persisting symptoms or had required urgent revision. We calculated the total cost savings of revision versus infusion tests and standard protocol of revision and ICP monitoring versus infusion tests. RESULTS: Three hundred sixty-five shunt infusion tests had been performed where a shunt prechamber/reservoir was present. For hydrocephalus patients, more than half of the tests (~ 55%, 155 out of 280) showed no shunt malfunction versus 125 with possible malfunction (ages 4 months to 90 years old). For PTCS patients aged 10 to 77 years old, 47 had possible problems and 38 no indication for shunt malfunction. Overall, > 290 unnecessary revisions were avoided over 3 years' time. Two hundred fifty-eight (> 85%) of those non-surgically managed, remained well, did not deteriorate and did not require surgery. No infections were associated with infusion studies. For Cambridge, the overall savings from avoiding revisions was £945,415 annually. CONCLUSIONS: Our results provide evidence of the importance of shunt testing in vivo to confirm shunt malfunction. Avoiding unnecessary shunt revisions carries a strong health benefit for patients that also translates to a significant financial benefit for the National Health Service and potentially for other healthcare systems worldwide.
引用
- Lalou AD, Czosnyka M, Garnett MR, et al. Shunt infusion studies: impact on patient outcome, including health economics. Acta Neurochir (Wien). 2020. PMID: 32078047. doi:10.1007/s00701-020-04212-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。